報價延遲最少15分鐘:2026/03/03 23:55 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
131.14 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
4.67/7.70
|
|
企業價值
13.70B
|
| 資產負債 |
|
每股賬面淨值
32.41
|
| 現金流量 |
|
現金流量率
0.06
|
| 損益表 |
|
收益
2.86B
|
|
每股收益
17.77
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products. |
